They have created innovative interventions that eliminate the need for eye drops and painful injections, making eye care more convenient and comfortable. In addition, iVeena develops implants that efficiently deliver drugs to both the front and back of the eye. With a focus on non-surgical and non-invasive solutions, iVeena is dedicated to addressing significant unmet needs in the treatment of corneal disease and myopic conditions.

Their lead programs consist of novel proprietary eye drops, including IVMED-80 for keratoconus (granted ODD) and IVMED-85 for myopia. iVeena has made significant strides in the field of ophthalmology, with achievements such as entering into a strategic licensing agreement with Glaukos Corporation for the development of an investigational keratoconus therapy. The company has also successfully completed a pre-IND meeting with the FDA, showcasing their commitment to advancing their product pipeline.

For those seeking transformational disease-modifying advances in the treatment of keratoconus and myopia, iVeena Delivery Systems is at the forefront of innovation. Contact them today to learn more about their groundbreaking solutions